From the aKing’s College London, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, London, United Kingdom; bDepartment of Medical Statistics, London School of Hygiene and Tropical Medicine, London, United Kingdom; and cCentre for Public Health Research, Massey University Wellington Campus, Wellington, New Zealand.
This is an EU Joint Programme—Neurodegenerative Disease Research (JPND) project. The project is supported through the following funding organizations under the aegis of JPND—http://www.jpnd.eu (Medical Research Council and Economic and Social Research Council, United Kingdom). A.A.-C. receives salary support from the National Institute for Health Research (NIHR) Dementia Biomedical Research Unit and Biomedical Research Centre in Mental Health at South London and Maudsley NHS Foundation Trust and King’s College London, London, United Kingdom. The work leading up to this publication was funded by the European Community’s Health Seventh Framework Programme (FP7/2007–2013; grant agreement number 259867). N.P. has no conflicts to report.
Correspondence: Ammar Al-Chalabi, Maurice Wohl Clinical Neuroscience Institute, King’s College London, Coldharbour Lane, London SE5 9NU, United Kingdom. E-mail: email@example.com.